Pfizer announces $5.2 billion acquisition of Anacor

16 May 2016
mergers-acquisitions-big

US pharma giant Pfizer (NYSE: PFE) said today that it plans to acquire Anacor Pharmaceuticals (Nasdaq: ANAC) for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of around $5.2 billion, which assumes the conversion of Anacor’s outstanding convertible notes.

Making their first acquisition announcement since abandoning the tax-inversion directed $160 billion buy of Ireland-incorporated Allergan, the Pfizer board of directors has unanimously approved the transaction, as has the board of Anacor. Pfizer expects to complete the acquisition in the third-quarter 2016.

Pfizer’s shares dipped 0.5% to $33.03 in early trading following the announcement, while Anacor’s stock leapt 54% to $98.70 in pre-market activity.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical